PRISTIQ 50mg price in UAE

Overview

Welcome to Dwaey, specifically on PRISTIQ 50mg Tablets/Extended Release page.
This medicine contains an important and useful components, as it consists of Desvenlafaxine (as succinate).
PRISTIQ 50mg is available in the market in concentration 50mg/Tablet and in the form of Tablets/Extended Release.

PF PRISM C.V is the producer of PRISTIQ 50mg and it is imported from NETHERLANDS, The most popular alternatives of PRISTIQ 50mg are listed downward .

Mode Of Action

Desvenlafaxine, the major active metabolite of venlafaxine, is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). Clinical efficacy of desvenlafaxine is thought to be related with the drug's potentiation of serotonergic and noradrenergic activity in the CNS. It does not have monoamine oxidase (MAO) inhibitory activity; and has not shown significant affinity for muscarinic cholinergic, H1-histaminergic, alpha-adrenergic, dopaminergic, gama-aminobutyric acid (GABA), glutamate, and opiate receptors in vitro. At concentrations that inhibit serotonin and norephinephrine reuptake, inhibition of dopamine reuptake appears to be unlikely.

Indication

Depression

Precaution

May be associated with increased risk of suicidal thinking and behaviour in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Monitor patients for clinical worsening of depression, emergence of suicidality, unusual changes in behaviour particularly during initiation of therapy and during dosage adjustments. Serotonin syndrome or neuroleptic malignant syndrome (NMS) have occurred with selective serotonin reuptake inhibitor (SSRI) or SNRI treatment alone; and particularly with concomitant use of MAOI, serotogenic agents (e.g. triptans), antipsychotics or dopamine antagonists. Gradually taper dose if discontinuing to reduce risk of withdrawal symptoms. May activate mania/hypomania, caution in patients with history or family history of mania or hypomania. Caution in patients with pre-existing glaucoma, hypertension, cardiovascular, cerebrovascular, or lipid metabolism and seizure disorders. Sustained elevations in blood pressure have been reported. May be associated with dose-related increase in serum total cholesterol, LDL, triglycerides. May increase risk of bleeding. May be associated with development of syndrome of inappropriate antidiuretic hormone (SIADH) and Hyponatraemia, elderly and patients who are taking diuretics or with volume depletion may be at greater risk. Interstitial lung disease and eosinophilic pneumonia associated with venlafaxine (the parent drug of desvenlafaxine) have been reported. Medications containing venlafaxine should not be used concomitantly. Renal and hepatic impairment. Safety and efficacy have not been established in paediatrics. Elderly. Pregnancy. Not recommended in lactation. Lactation: Drug is excreted in breast milk; discontinue drug, or do not nurse; use only if benefits greatly outweigh risks

Side Effects

>10% Nausea (22-41%)
Headache (20-29%)
Dry mouth (11-25%)
Hyperhidrosis (10-21%)
Dizziness (13-16%)
Insomnia (9-15%)
Constipation (9-14%)
Fatigue (7-11%)
Diarrhea (5-11%) 1-10% Decreased appetite (5-10%)
Anxiety (0-10%)
Elevated cholesterol and triglycerides (0-10%)
Insomnia (0-10%)
Tremor (2-9%)
Proteinuria (5-8%)
Mydriasis (2-6%)
Male sexual dysfunction (0-6%)
Anxiety (3-5%)
Vertigo (1-5%)
Blurred vision (3-4%)
Abnormal dreams (2-4%)
Urinary hesitation (2-4%)
Yawning (1-4%)
Feeling jittery (1-3%)
Female sexual dysfunction (0-3%)
Irritability (2%) Other (eg
abnormal liver function tests
increased blood prolactin
convulsion
syncope
extrapyramidal disorders
musculoskeletal stiffness
depersonalization
hypomania
bruxism
epistaxis
orthostatic hypotension) (<2%) Asthenia (1-2%)
Nervousness (1-2%)
Hot flush (1-2%)
Rash (1-2%) Frequency Not Defined Ischemic cardiac events in patients with multiple underlying cardiac risk factors Gastrointestinal (GI) bleeding
hallucinations
photosensitivity reactions and severe cutaneous reactions (eg
Stevens-Johnson syndrome
toxic epidermal necrolysis
erythema multiforme) have occurred with other serotonin-norepinephrine reuptake inhibitors (SNRIs) or selective serotonin reuptake inhibitors (SSRIs) Suicidal thoughts and behaviors in adolescents and young adults Hyponatremia
Interstitial lung disease and eosinophilic pneumonia
Serotonin syndrome
Elevated blood pressure
Abnormal bleeding
Narrow-angle glaucoma
Activation of mania or hypomania
Discontinuance syndrome
Seizure Potentially Fatal: Serotonin syndrome or neuroleptic malignant syndrome-like reactions.

Contra indication

Hypersensitivity to Desvenlafaxine, venlafaxine or any component of the formulation. Concomitant/recent (within preceeding 14 days) use of MAOI. Do not initiate MAOI at least 7 days after discontinuing Desvenlafaxine.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

Desvenlafaxine may diminish the therapeutic effect of Iobenguane I-123. May enhance adverse effects of other CNS depressants. Sibutramine and MAOI may enhance the serotonergic effect of Desvenlafaxine; increase risk of development of serotonin syndrome. Concomitant use with alpha-/beta-agonists may enhance tachycardic and vasopressor effect. Desvenlafaxine may increase concentration of CYP2D6 substrates (e.g. desipramine); decrease exposure of CYP3A4 substrates (e.g. midazolam). CYP3A4 inhibitors (e.g. ketoconazole) may increase concentration of desvenlafaxine. May enhance the antiplatelet effect of nonselective NSAIDs, aspirin; and anticoagulant effect of warfarin. Potentially Fatal: Concurrent use with MAOIs may lead to fatal serotonin syndrome or NMS-like reactions. Do not use within at least 14 days of discontinuing MAOI treatment and start MAOI at least 7 days after stopping desvenlafaxine. Increased risk of serotonin syndrome with sibutramine.